Japan System Techniques Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Despite higher revenue, earnings declined due to a lower gross margin and the recognition of an impairment loss, resulting in higher revenue but lower earnings. Revenue increased to ¥7.44B (+5.6% YoY), while Operating Income declined to ¥0.39B (-21.0%) and Ordinary Income fell to ¥0.40B (-21.0%). Net Income decreased substantially to ¥0.14B (-56.9%), primarily due to the one-time factor of a ¥0.16B impairment loss on fixed assets. The gross margin was 24.7%, down from the previous year, and the inability to absorb the top-line growth at the earnings level was a key feature of the current period.

Factors Behind Performance Changes

【Revenue】Revenue increased to ¥7.44B (+5.6% YoY). By segment, DXAndSI was the largest growth driver at ¥4.85B (+5.7%, 65% of total), while MedicalBigData also posted strong growth of ¥0.65B (+14.7%). Package increased to ¥1.44B (+3.3%), while Global was ¥0.51B (-1.5%), showing somewhat sluggish growth.

【Profit and Loss】Operating Income declined to ¥0.39B (-21.0%), and Ordinary Income fell to ¥0.40B (-21.0%). The gross margin declined to 24.7% from the previous year, and although the SG&A ratio improved to 19.5%, this was insufficient to absorb the decline in gross margin. Net Income deteriorated further to ¥0.14B (-56.9%), primarily due to the one-time factor of a ¥0.16B impairment loss on shared assets, recorded as an extraordinary loss, resulting in a significant divergence between Ordinary Income and Net Income. The effective tax rate was also high at 42.6%, and the limited tax effect associated with the impairment further compressed profit after tax. In conclusion, the current period resulted in higher revenue but lower earnings.

Segment Analysis

DXAndSI generated revenue of ¥4.85B (+5.7%) and Operating Income of ¥0.82B (-0.2%, margin of 16.9%), making it the Company’s leading earnings contributor and maintaining earnings almost fully despite higher revenue. Package generated revenue of ¥1.44B (+3.3%) and Operating Income of ¥0.28B (-24.8%, margin of 19.4%); although its margin remained at the highest level, profitability deteriorated. MedicalBigData posted strong revenue growth of ¥0.65B (+14.7%), but Operating Income was ¥0.03B (-40.1%, margin of 4.8%), indicating continued low profitability while the business remains in the scaling phase. Global generated revenue of ¥0.51B (-1.5%) and an Operating Loss of ¥0.05B (45.0% reduction in the loss compared with the previous year), showing an improving trend but remaining in the red. Company-wide, the stability of DXAndSI and fluctuations in the profitability of the other segments are increasing the range of movement in the overall profit margin.

Key Financial Indicators

【Profitability】The Operating Income margin declined to 5.2% from the previous year, while the Net Income margin remained at approximately 1.9%. The gross margin was 24.7%, down approximately 2.7pt from the previous year, presumably due to changes in project mix and utilization rates.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥3.50B, significantly exceeding Net Income of ¥0.14B, indicating strong cash-generation capacity. A ¥3.14B cash inflow from the decrease in trade receivables and a ¥1.29B increase in contract liabilities boosted cash flow.【Investment Efficiency】ROE was low at 0.9%, primarily due to the contraction in Net Income. Asset turnover efficiency relative to total assets showed no significant change, while financial leverage remained low and stable.【Financial Soundness】The Equity Ratio was high at 62.4%, and cash and deposits of ¥11.73B accounted for approximately 45% of total assets. Interest-bearing debt was immaterial, indicating a conservative capital structure.

Cash Flow Analysis

Operating Cash Flow was ¥3.50B, down -13.7% YoY, but still substantially exceeded Net Income of ¥0.14B, demonstrating strong cash generation. The primary factors were ¥3.14B in cash realization from the decrease in trade receivables and the accumulation of advance receipts associated with a ¥1.29B increase in contract liabilities. Billing and collection progress on projects and the recurring nature of advance receipts supported cash flow. Investing Cash Flow was a modest ¥0.02B, while capital expenditures were a minor ¥0.03B, with no large-scale investments undertaken. Financing Cash Flow was -¥0.85B, primarily reflecting cash outflows from dividend payments. As a result, free cash flow was a substantial ¥3.52B, sufficiently covering dividend payments and indicating considerable financial flexibility.

Quality of Earnings

Compared with earnings at the Ordinary Income level—Operating Income of ¥0.39B and a small positive non-operating balance of approximately ¥0.02B—Net Income for the period was significantly affected by the ¥0.16B impairment loss recorded as an extraordinary loss. The divergence from Ordinary Income of ¥0.40B to Net Income of ¥0.14B resulted from the extraordinary loss and the high effective tax rate of 42.6%, which depressed Net Income more than the change in recurring earnings power alone would suggest. Non-operating income consisted primarily of interest and dividend income and was limited to approximately 0.2% of revenue, indicating a small contribution from outside the core business. From an accrual perspective, however, OCF substantially exceeded Net Income, indicating good cash-based earnings quality. The deterioration in Net Income during the current period was significantly affected by one-time factors; from the perspective of sustainable earnings power, trends in Operating Income and Ordinary Income are more important indicators.

Earnings Forecast and Guidance

Progress against the full-year plan was 21.7% for Revenue (¥7.44B/¥34.30B), 9.4% for Operating Income (¥0.39B/¥4.15B), and 9.6% for Ordinary Income (¥0.40B/¥4.20B), below the simple one-quarter progress benchmark of 25%. Progress in Operating Income and Ordinary Income was particularly weak, reflecting the decline in gross margin and the impact of the one-time impairment loss. Neither the earnings forecast nor the dividend forecast has been revised, and management has maintained its current plan. Contract liabilities have accumulated to ¥1.79B, equivalent to approximately 24% of quarterly revenue in advance receipts, and may support revenue toward the second half of the fiscal year.

Shareholder Returns

The Company’s annual dividend forecast is ¥50, representing an increase from the previous year’s dividend of ¥11 (quarterly presentation). Based on forecast EPS of ¥119.34, the Payout Ratio is approximately 41.9%, and dividend payments of ¥0.84B are sufficiently covered by free cash flow of ¥3.52B for the current quarter. There has been no revision to the current period’s dividend forecast, and the existing plan remains unchanged. Supported by substantial cash and deposits of ¥11.73B, dividend sustainability is considered high.

Risk Factors

1. Project profitability risk: The gross margin declined to 24.7% from the previous year, and, as indicated by the deterioration in the profit margins of Package and MedicalBigData (-24.8% and -40.1%, respectively), the business structure is susceptible to the impact of changes in project mix and utilization rates.

2. Risk of recurrence of one-time losses: The Company recorded a ¥0.16B impairment loss on shared assets during the current period. If the review of the asset composition continues, additional one-time expenses may arise.

3. Segment concentration risk: DXAndSI accounts for 65% of the revenue composition, creating a structure in which demand trends and changes in the project mix in this business could have a significant impact on company-wide performance.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (it_telecom)

Profitability and Returns

Compared with the industry median, both the Operating Income margin and Net Income margin are lower, placing profitability relatively low within the industry.

Growth and Capital Efficiency

The Revenue growth rate also falls somewhat below the industry median, placing the Company’s growth speed at the lower end of the industry.

※Source: Company analysis

Key Takeaways from the Earnings Results

1. While revenue increased steadily, the decline in gross margin resulted in lower Operating Income, and the one-time impairment loss led to a substantial decrease in Net Income. The coexistence of higher revenue and lower earnings is an area requiring monitoring from a cost and profitability perspective.

2. OCF was generated at a level substantially exceeding Net Income, and cash-generation capacity supported by the accumulation of contract liabilities (advance receipts) was strong. The balance sheet was also conservative, with an Equity Ratio of 62.4%, indicating high financial soundness.

3. Progress against the full-year plan was below the standard progress benchmark of 25% for both revenue and earnings, with delays in Operating Income and Ordinary Income particularly notable. The accumulation of contract liabilities should be monitored as a factor supporting future revenue.

Theoretical Share Price (Reference Value)

Sensitivity: ¥813–¥860 at a ±1% change in the cost of equity, and ¥831–¥843 at a change of ±0.1 in ω.

Notes:

• Goodwill amortization of ¥0.8 per share has been added back to earnings (due to its non-cash nature and to improve comparability with IFRS companies).
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these values are not forecasts of the market share price or recommendations for any specific investment action, and do not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and, where necessary, after consulting with a professional.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a mixed quarter: revenue grew, but operating profitability weakened materially and a one-off impairment drove a sharp decline in bottom-line profit. Revenue increased 5.6% year on year to ¥7.44bn. Operating income fell 21.0% to ¥390m, reducing the operating margin to 5.2% from 7.0% a year earlier, a 176bp contraction. Gross profit declined 4.8% to ¥1.84bn despite top-line growth. Consequently, gross margin compressed by approximately 271bp to 24.7% from 27.5%, indicating higher delivery costs or an unfavorable project and product mix. SG&A was broadly flat at ¥1.45bn, up only 0.8%, so the primary margin pressure was in cost of sales rather than overhead growth. Ordinary income also declined 21.0% to ¥402m. Profit attributable to owners of the parent fell 64.8% to ¥113m, with EPS declining to ¥4.59 from ¥13.02. The principal cause of the disproportionate net-profit decline was a ¥156m extraordinary impairment loss on a shared asset designated for sale. The effective tax rate was 42.6%, also above a normal Japanese corporate tax range and further constraining reported earnings. Operating cash flow was exceptionally strong at ¥3.50bn and free cash flow was ¥3.52bn, but this mainly reflected a ¥3.14bn reduction in receivables and a ¥1.29bn increase in contract liabilities. Thus, cash generation is strong in the reported quarter but should not be extrapolated directly as recurring cash conversion. The balance sheet remains highly liquid, with cash and deposits of ¥11.73bn, a 252.1% current ratio, and only ¥41m of long-term loans. Full-year revenue guidance of ¥34.30bn implies Q1 progress of 21.7%, slightly below the standard 25% seasonal benchmark. Operating-income progress is only 9.4% of the ¥4.15bn full-year target, meaning a substantial margin recovery is required through the remainder of the year. Management has not revised either earnings or dividend guidance, and the forecast DPS of ¥50 implies a forecast dividend payout ratio of about 41.9% against EPS guidance of ¥119.34.

Profitability Analysis

The reported annualized ROE is 2.8%, below the 8% level generally viewed as an adequate return threshold. The three-factor DuPont decomposition is an annualized 1.5% net profit margin, 1.150x asset turnover, and 1.60x financial leverage. The weakest component is net margin, which was heavily reduced by the impairment loss and elevated tax burden; the business is not relying on excessive financial leverage to generate returns. Asset turnover is reasonable for an IT services and package-software-oriented group, while leverage remains moderate at 1.60x on an assets-to-equity basis. The operating margin of 5.2% is above the 5% concern threshold only marginally and represents a meaningful deterioration from the prior-year quarter. Gross-margin compression was the key operating issue, as gross profit fell even though revenue increased. SG&A growth of 0.8% was well below revenue growth of 5.6%, providing some operating-leverage support but insufficient to offset the decline in gross margin. The five-factor tax burden of 0.458 reflects the large gap between profit before tax and profit attributable to owners, while the reported interest-burden alert is not a debt-servicing issue in substance: interest expense was only ¥2m and interest coverage was 218.7x. Rather, the low EBT/EBIT relationship was principally caused by the ¥156m extraordinary impairment booked below operating income. JGAAP goodwill amortization was only ¥5m, or roughly 1.1% of EBITDA, and therefore does not materially distort comparison with IFRS reporters. Segmentally, the DX & SI business is the core business by segment profit contribution, producing ¥820m of segment profit on ¥4.85bn of revenue. DX & SI revenue grew 5.7%, but segment profit was broadly flat year on year, with its margin declining to 16.9% from 17.9%. Package business revenue grew 3.3%, while segment profit fell 24.8% to ¥280m and margin declined sharply to 19.4% from 26.7%. Medical big-data revenue grew the fastest, up 15.0% to ¥651m, but segment profit fell 40.1% to ¥31m and margin halved to 4.8% from 9.2%. Global business revenue was nearly flat at ¥491m, but its segment loss narrowed to ¥49m from ¥89m, improving margin to negative 9.7% from negative 18.3%. Corporate and unallocated costs increased to ¥693m from ¥664m, further reducing consolidated operating income.

Growth Assessment

Revenue growth of 5.6% is broadly consistent with the full-year revenue-growth outlook of 5.7%, suggesting that demand remains intact across the major domestic businesses. Growth was led by the medical big-data business, followed by DX & SI, while package revenue expanded more modestly and global revenue was essentially flat. However, segment profit trends show that revenue growth is currently not converting effectively into earnings growth. In particular, the package and medical big-data segments require margin stabilization for the company to meet its full-year operating-income plan. Q1 operating income of ¥390m represents 9.4% of the ¥4.15bn full-year forecast, 15.6 percentage points below the standard Q1 progress rate of 25%. Ordinary income progress is similarly only 9.6% of the ¥4.20bn full-year forecast. Profit attributable to owners is 3.8% of the ¥2.95bn annual forecast, although this measure is depressed by the Q1 impairment. The absence of a forecast revision indicates that management expects later-quarter earnings concentration and/or normalization of Q1-specific costs. The impairment appears non-recurring because it relates to an asset for which a sale decision was made, but it reduces the cushion for full-year earnings delivery. Contract liabilities increased to ¥1.79bn from ¥0.51bn a year earlier, providing evidence of advance customer billings and potentially supporting subsequent revenue recognition. Revenue sustainability will depend on continued DX & SI demand, improved package-business project economics, and the path to profitability in the global operation. For an IT-services group, project execution, personnel utilization, wage inflation, and the ability to pass costs through to customers remain central determinants of margin recovery.

Financial Health

Financial health is robust. Current assets of ¥19.35bn exceed current liabilities of ¥7.68bn by ¥11.68bn, producing a current ratio of 252.1% and a quick ratio of 250.0%. Therefore, there is no current-liquidity or short-term maturity-mismatch concern. Cash and deposits increased 28.7% year on year to ¥11.73bn and represent 45.3% of total assets. Trade receivables declined 34.3% year on year to ¥5.98bn, improving cash availability, although reported DSO of 73 days remains above the 60-day quality-alert threshold and should be monitored for collection timing. Inventories increased 39.7% to ¥156m, but remain only 0.6% of total assets and are not material to overall liquidity. Work in process accounts for 48.4% of inventory, above the 40% alert threshold, which raises execution and cost-overrun risk for unfinished projects despite the small absolute balance. Total liabilities are 37.6% of assets, while total equity is ¥16.15bn. Interest-bearing debt is limited to ¥41m of long-term loans, equivalent to only 0.3% of capital, and debt/EBITDA is 0.09x. The reported debt-to-equity ratio is 0.60x, still well below the 2.0x warning threshold, while the identified interest-bearing-loan balance indicates very low conventional borrowing risk. Interest coverage of 218.7x and EBITDA interest coverage of 242.7x confirm that financing costs are immaterial. Asset retirement obligations total ¥574m, or 6.7% of liabilities according to the quality alert, exceeding the 5% alert threshold; this is a meaningful long-dated obligation that should be monitored alongside the underlying facilities and restoration assumptions. Goodwill is only ¥155m, equal to 1.0% of equity and 0.6% of assets, so balance-sheet dependence on acquired-business value is low. Intangible assets are also modest at 1.7% of assets. The ¥9.26bn deferred-tax-asset balance is material relative to assets and equity, making future taxable-income generation relevant to the recoverability of this asset.

Notable B/S Changes

Cash and deposits: +¥2.62bn (+28.7%) to ¥11.73bn - driven by strong reported operating cash flow, principally the quarter's receivable collection and contract-liability movements; materially strengthens liquidity. Accounts receivable: -¥3.13bn (-34.3%) to ¥5.98bn - a major source of Q1 operating cash flow; collection timing should be monitored given reported DSO of 73 days. Inventories: +¥44m (+39.7%) to ¥156m - still immaterial at 0.6% of assets, but the high work-in-process share raises project-completion and cost-control monitoring requirements. Contract liabilities: +¥1.29bn to ¥1.79bn from ¥0.51bn - indicates increased advance billing or customer prepayments, supports near-term cash flow, and may provide a revenue-recognition base for subsequent periods. Retained earnings: -¥731m (-5.8%) to ¥11.91bn - reflects ¥844m of cash dividends paid exceeding Q1 owner-attributable profit of ¥113m. Deferred tax assets: +¥258m (+38.6%) to ¥926m - material asset increase that increases the importance of future taxable-profit generation for recoverability.

Cash Flow Quality

Reported operating cash flow was ¥3.50bn, equal to 31.0x reported net income of ¥113m, and free cash flow was ¥3.52bn after only ¥30m of capital expenditures. The OCF/net-income ratio is well above the 1.0x benchmark and the accruals ratio of negative 13.1% is favorable mechanically. However, the quarter's cash conversion was dominated by working-capital movements rather than underlying quarterly profitability. Trade receivables and contract assets decreased by ¥3.14bn, and contract liabilities increased by ¥1.29bn, creating a substantial cash inflow from customer settlement and advance billing. These movements explain why operating cash flow materially exceeds EBITDA of ¥433m and why cash conversion measured as OCF/EBITDA reached 8.09x. The resulting cash flow is real, but it is unlikely to be a sustainable run-rate without similar recurring billing and collection timing. A ¥906m reduction in bonus provisions partly offset these working-capital inflows. Trade payables decreased by ¥309m, representing a cash outflow. Capital expenditures of ¥30m were below depreciation and amortization of ¥43m, resulting in a 0.70x capex/depreciation ratio. This sits at the underinvestment warning boundary and warrants monitoring, especially if software, delivery capacity, security, and platform investment are needed to support the DX and medical-data growth agenda. Financing cash flow was negative ¥853m, chiefly reflecting ¥844m of cash dividends paid. Investing cash flow was slightly positive at ¥18m, and there was no evidence of acquisition-led cash deployment. Cash increased by ¥2.67bn in the quarter to ¥11.73bn, reinforcing liquidity but largely reflecting the exceptional working-capital release.

Dividend Sustainability

The company forecasts a full-year DPS of ¥50 and has not revised its dividend outlook. Based on forecast EPS of ¥119.34, the prospective dividend payout ratio is approximately 41.9%, below the 60% sustainability benchmark. This indicates that the stated dividend can be covered by forecast earnings if management achieves its annual profit plan. Q1 owner-attributable earnings of ¥113m alone do not cover a full-year dividend obligation, but quarterly earnings are not the appropriate basis for judging the annual policy because the company has a full-year forecast and Q1 included a ¥156m impairment loss. Q1 free cash flow of ¥3.52bn provides ample near-term cash coverage, although it was materially supported by favorable working-capital timing. The balance sheet offers a further dividend buffer through ¥11.73bn of cash and negligible interest-bearing debt. Cash dividends paid during Q1 were ¥844m, exceeding Q1 reported earnings, which reduced retained earnings year on year. Dividend sustainability therefore depends primarily on delivery of the forecast operating-income recovery, rather than on liquidity or debt capacity. The absence of a dividend revision signals management confidence, but investors should monitor whether package and medical big-data segment margins recover sufficiently to support the full-year EPS plan.

Risk Assessment

Business risks include Project profitability risk: gross margin declined by about 271bp, while package-business and medical-big-data segment margins fell materially despite revenue growth., DX & SI execution risk: the core business generated ¥820m of segment profit but was flat year on year despite 5.7% revenue growth, indicating limited current conversion of growth into profit., Medical big-data commercialization risk: revenue grew 15.0%, but segment profit declined 40.1% and margin fell to 4.8%, leaving limited margin resilience., Global business turnaround risk: the segment loss narrowed but remained ¥49m, or a negative 9.7% margin; a delayed path to profitability would weigh on consolidated earnings., IT-services industry risk: skilled-labor costs, recruitment and retention, project delays, cost overruns, cybersecurity requirements, and technology shifts can pressure utilization and delivery margins., Work-in-process risk: WIP represents 48.4% of inventories, above the quality-alert threshold, and could lead to additional cost provisions or write-downs if projects do not progress as expected..

Financial risks include Earnings-quality risk: Q1 operating cash flow was boosted by a ¥3.14bn receivables reduction and ¥1.29bn contract-liability increase, so the ¥3.50bn OCF should not be treated as a recurring quarterly level., Receivable-collection risk: DSO of 73 days exceeds the 60-day alert threshold, notwithstanding the substantial year-on-year receivables decline., Tax-rate risk: the reported effective tax rate was 42.6%, and the low tax-burden measure reduces conversion of pre-tax profit into owner earnings., Asset-retirement-obligation risk: AROs of ¥574m equal 6.7% of liabilities under the alert methodology and may require future cash settlement depending on facility closures and restoration timing., Deferred-tax-asset recoverability risk: deferred tax assets of ¥926m are material and depend on sufficient future taxable income..

Key concerns include The ¥156m impairment was 137.9% of owner-attributable net income and demonstrates that one-time charges can have an outsized impact on quarterly EPS., Operating-income progress of 9.4% versus the 25% standard Q1 benchmark requires a pronounced second-half earnings recovery to meet the ¥4.15bn full-year plan., Capex/depreciation of 0.70x is at the underinvestment warning level; persistent underspending could constrain future growth capacity or technology competitiveness., The quality-alert interest-burden measure should be interpreted carefully: the apparent 37% EBIT-to-EBT reduction principally reflects the extraordinary impairment, not financial leverage, as interest expense was only ¥2m and coverage was very high..

Investment Implications

Key takeaways include Top-line momentum remains positive, with 5.6% consolidated revenue growth and particularly strong 15.0% growth in medical big data., Profitability is the principal issue: operating margin fell to 5.2%, and both package and medical-big-data segment margins deteriorated sharply., The Q1 net-profit decline was amplified by a ¥156m impairment; excluding this item, underlying pre-tax earnings would have been materially higher, though operating-income weakness would remain., Liquidity and debt capacity are substantial, supported by ¥11.73bn in cash, a 252.1% current ratio, 0.09x debt/EBITDA, and 218.7x interest coverage., The annual guidance framework requires significant later-quarter earnings delivery, especially for operating income and owner-attributable profit., M&A and goodwill risk are low: goodwill is only 1.0% of equity, 0.36x EBITDA, and goodwill amortization is immaterial..

Metrics to watch include Consolidated gross margin and operating margin recovery relative to the Q1 levels of 24.7% and 5.2%, Package-business segment margin after its decline to 19.4%, Medical-big-data segment margin and progress toward scalable profitability from the current 4.8%, Global-business loss reduction from the Q1 loss of ¥49m, Receivable days and the durability of contract-liability growth, Operating-income progress toward the ¥4.15bn full-year forecast, Capital expenditures relative to depreciation and investment in software and delivery capability, Any additional impairment charges and the recoverability of deferred tax assets.

Regarding relative positioning, The company combines a strong net-cash-like liquidity profile and limited M&A balance-sheet risk with suboptimal near-term profitability. Its Q1 operating margin of 5.2% is below the 8% level generally associated with stronger IT-services profitability, while the low leverage means future return improvement must come primarily from margin recovery and efficient revenue growth rather than balance-sheet gearing.